Lycopid, tablets 1 mg 10 pcs

Pharmacodynamics

The active ingredient of Lycopid® tablets – glucosaminylmuramyldipeptide (GMDP) – is a synthetic analog of the structural fragment of the shell (peptidoglycan) of bacterial cells. GMDP is an activator of innate and acquired immunity, enhances the body’s defense against viral, bacterial and fungal infections; it has an adjuvent effect in the development of immunological reactions.

Likopid® has low toxicity (LD50 exceeds the therapeutic dose 106 000 times and more). In experiment at oral administration with doses 100 times higher than the therapeutic one the drug does not have toxic effect on the central nervous and cardiovascular systems, does not cause pathological changes of internal organs. Lycopid® has no embryotoxic and teratogenic effect and does not cause chromosomal and gene mutations. In experimental studies performed on animals the data about the antitumor activity of Lycopid® (GMDP) was received.

Pharmacokinetics

The bioavailability of the drug with oral administration is 7-13%. The degree of binding to blood albumin is weak. Time of reaching maximum concentration (tmax) is 1.5 hours after intake. Elimination half-life (t1/2) is 4.29 hours. It does not form active metabolites, it is excreted mainly through the kidneys unchanged.

Indications

The drug is used in adults and children (from 3 years) in the treatment of diseases accompanied by secondary immunodeficiency states:

Children

Chronic, recurrent upper and lower respiratory tract infections in the acute and in remission;

• acute and chronic inflammatory diseases of the skin and soft tissue (pyoderma, furunculosis, etc.);
• herpetic infection.

Adults

Chronic respiratory tract infections;

• Acute and chronic purulent inflammatory diseases of the skin and soft tissues (pyoderma, furunculosis and others);
• herpetic infection.

Preventive treatment (adults)

Prevention and reduction of the seasonal incidence of acute respiratory diseases and the frequency of exacerbations of chronic diseases of the ENT organs, upper and lower respiratory tract.

Active ingredient

Glucosaminylmuramyldipeptide

Composition

Active ingredient: glucosaminylmuramyldipeptide (GMDP) – 1.0 mg. Excipients: lactose monohydrate – 73.88 mg, sucrose (sugar) – 5.0 mg, potato starch – 19.0 mg, methylcellulose – 0.12 mg, calcium stearate – 1.0 mg.

How to take, the dosage

Lycopid® is taken orally or sublingually on an empty stomach, 30 minutes before a meal.

If you miss a dose, if no more than 12 hours have passed from the scheduled time, you can take the missed dose; if more than 12 hours have passed from the scheduled time, you should only take the next scheduled dose and not take the missed dose.

Dose adjustment is not necessary in certain patient groups (elderly patients, patients with hepatic impairment, patients with impaired renal function).

Children:

Acute and chronic purulent inflammatory diseases of the skin and soft tissue (pyoderma, furunculosis and others): 1 tablet once a day under the tongue for 10 days.

Chronic, recurrent infections of the upper and lower respiratory tract (acute and remission): Licopid® is taken in 3 courses of 1 tablet once daily under the tongue for 10 days, with a break of 20 days between courses.

Herpetic infection: 1 tablet 3 times daily orally or under the tongue for 10 days.

Adults:

Chronic respiratory tract infections: up to 2 tablets once daily under the tongue for 10 days.

Acute and chronic purulent inflammatory diseases of the skin and soft tissues (pyoderma, furunculosis and others): 2 pills 2-3 times a day under the tongue for 10 days.

Herpetic infection: 2 tablets 3 times a day orally or under the tongue for 10 days.

Prevention (adults):

Likopid® for prevention or reduction of the seasonal incidence of SARS and the frequency of exacerbations of diseases of the ENT organs, upper and lower respiratory tract take 1 tablet 3 times daily under the tongue for 10 days.

Precautionary measures for use:

Each Lycopid® 1 mg tablet contains 0.00042 x.u. (bread units) sucrose, which should be considered in patients with diabetes.

Each tablet of Lycopid® 1 mg contains 0.074 grams of lactose, which should be considered by patients with hypolactasia (lactose intolerance, in which the body has reduced levels of lactase, an enzyme needed to digest lactose).

Interaction

The drug increases the effectiveness of antimicrobial drugs, synergism with respect to antiviral and antifungal drugs is noted. Antacids and sorbents significantly reduce the bioavailability of the drug. Glucocorticosteroids reduce the biological effect of Lycopid®.

Special Instructions

In the beginning of Likopid® 1 mg use, exacerbation of symptoms of chronic and latent diseases related to the main pharmacological effects of the drug is possible.

Influence on ability to drive vehicles, machinery Does not affect the ability to drive and operate complex machinery.

Indications on ability to drive vehicles, machinery.

Synopsis

Round flat cylindrical white beveled tablets.

Contraindications

Hypersensitivity to glucosaminylmuramyldipeptide and other drug components;

pregnancy and breastfeeding; autoimmune thyroiditis in the acute phase;

Conditions accompanied by febrile fever (>38°C) at the time of taking the drug;

Rare congenital metabolic disorders: alactasia, galactosemia, lactase deficiency, lactose intolerance, sucrose/isomaltase deficiency, fructose intolerance, glucose-galactose malabsorption;

The use in autoimmune diseases is not recommended due to lack of clinical data.

Side effects

Frequently (1-10%) – at the beginning of treatment there may be short-term increase in body temperature to subfebrile values (up to 37.9 ° C), which is not an indication for withdrawal of the drug.

Rarely (0.01-0.1%) – short-term increase in body temperature to febrile values (>38.0 ° C). If the body temperature is higher than 38.0 ° C, it is possible to take antipyretic drugs, which do not reduce the pharmacological effects of Lycopid® tablets.

very rarely (less than 0.01%) – diarrhea.

If any of the side effects listed in the instructions worsen, or if you notice any other side effects not listed in the instructions, tell your doctor.

Overdose

There are no known cases of overdose of the drug. Based on the pharmacological properties of the drug, in case of overdose there may be a rise in body temperature to subfebrile (up to 37.9 ° C) values. If necessary, symptomatic therapy is carried out (antipyretic drugs), sorbents are prescribed. A specific antidote is not known.

Pregnancy use

The drug Lycopid® 1 mg is contraindicated for women during pregnancy and breastfeeding.